Literature DB >> 22241719

The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma.

E Patterson1, R Webb, A Weisbrod, B Bian, M He, L Zhang, A K Holloway, R Krishna, N Nilubol, K Pacak, E Kebebew.   

Abstract

Currently, the diagnosis of malignant pheochromocytoma can only be made when there is clinical evidence of metastasis or extensive local invasion. Thus, there is a need for new diagnostic marker(s) to identify tumors with malignant potential. The purpose of this study was to identify microRNAs (miRNAs) that are differentially expressed between benign and malignant pheochromocytomas and assess their diagnostic accuracy. Toward this aim, we analyzed miRNA expression in benign and malignant pheochromocytoma tumor samples using whole genome microarray profiling. Microarray analysis identified eight miRNAs that were significantly differentially expressed between benign and malignant pheochromocytomas. We measured a subset of these miRNAs directly by RT-PCR and found that miR-483-5p, miR-183, and miR-101 had significantly higher expression in malignant tumors as compared to their benign counterparts. Area under the receiver operating curve (AUC) analysis indicated that miR-483-5p, miR-101, and miR-183 could be useful diagnostic markers for distinguishing malignant from benign pheochromocytomas. In addition, these miRNAs could be detected in pheochromocytoma patient serum. Overall our data suggest that misexpression of miR-483-5p, miR-101, and miR-183 is associated with malignant pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22241719      PMCID: PMC4716660          DOI: 10.1530/ERC-11-0308

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  23 in total

1.  Use of within-array replicate spots for assessing differential expression in microarray experiments.

Authors:  Gordon K Smyth; Joëlle Michaud; Hamish S Scott
Journal:  Bioinformatics       Date:  2005-01-18       Impact factor: 6.937

Review 2.  Malignant pheochromocytoma.

Authors:  Rasa Zarnegar; Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  Surg Oncol Clin N Am       Date:  2006-07       Impact factor: 3.495

3.  SDHB loss predicts malignancy in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia signalling.

Authors:  Annika Blank; Anja M Schmitt; Esther Korpershoek; Francien van Nederveen; Thomas Rudolph; Nicole Weber; Räto Thomas Strebel; Ronald de Krijger; Paul Komminoth; Aurel Perren
Journal:  Endocr Relat Cancer       Date:  2010-10-05       Impact factor: 5.678

4.  Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas.

Authors:  Li Yao; Francesca Schiavi; Alberto Cascon; Yuejuan Qin; Lucia Inglada-Pérez; Elizabeth E King; Rodrigo A Toledo; Tonino Ercolino; Elena Rapizzi; Christopher J Ricketts; Luigi Mori; Mara Giacchè; Antonella Mendola; Elisa Taschin; Francesca Boaretto; Paola Loli; Maurizio Iacobone; Gian-Paolo Rossi; Bernadette Biondi; José Viana Lima-Junior; Claudio E Kater; Marie Bex; Miikka Vikkula; Ashley B Grossman; Stephen B Gruber; Marta Barontini; Alexandre Persu; Maurizio Castellano; Sergio P A Toledo; Eamonn R Maher; Massimo Mannelli; Giuseppe Opocher; Mercedes Robledo; Patricia L M Dahia
Journal:  JAMA       Date:  2010-12-15       Impact factor: 56.272

5.  Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.

Authors:  Diana E Benn; Anne-Paule Gimenez-Roqueplo; Jennifer R Reilly; Jérôme Bertherat; John Burgess; Karen Byth; Michael Croxson; Patricia L M Dahia; Marianne Elston; Oliver Gimm; David Henley; Philippe Herman; Victoria Murday; Patricia Niccoli-Sire; Janice L Pasieka; Vincent Rohmer; Kathy Tucker; Xavier Jeunemaitre; Deborah J Marsh; Pierre-François Plouin; Bruce G Robinson
Journal:  J Clin Endocrinol Metab       Date:  2005-11-29       Impact factor: 5.958

6.  MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy.

Authors:  Erin E Patterson; Alisha K Holloway; Julie Weng; Tito Fojo; Electron Kebebew
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

7.  Germline mutations in TMEM127 confer susceptibility to pheochromocytoma.

Authors:  Yuejuan Qin; Li Yao; Elizabeth E King; Kalyan Buddavarapu; Romina E Lenci; E Sandra Chocron; James D Lechleiter; Meghan Sass; Neil Aronin; Francesca Schiavi; Francesca Boaretto; Giuseppe Opocher; Rodrigo A Toledo; Sergio P A Toledo; Charles Stiles; Ricardo C T Aguiar; Patricia L M Dahia
Journal:  Nat Genet       Date:  2010-02-14       Impact factor: 38.330

8.  Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.

Authors:  Anne-Paule Gimenez-Roqueplo; Judith Favier; Pierre Rustin; Claudine Rieubland; Malvina Crespin; Valérie Nau; Philippe Khau Van Kien; Pierre Corvol; Pierre-François Plouin; Xavier Jeunemaitre
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

9.  Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.

Authors:  Laurence Amar; Eric Baudin; Nelly Burnichon; Séverine Peyrard; Stéphane Silvera; Jérôme Bertherat; Xavier Bertagna; Martin Schlumberger; Xavier Jeunemaitre; Anne-Paule Gimenez-Roqueplo; Pierre-François Plouin
Journal:  J Clin Endocrinol Metab       Date:  2007-07-24       Impact factor: 5.958

Review 10.  Clinical aspects of SDHx-related pheochromocytoma and paraganglioma.

Authors:  Henri J L M Timmers; Anne-Paule Gimenez-Roqueplo; Massimo Mannelli; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2009-02-03       Impact factor: 5.678

View more
  29 in total

1.  Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?

Authors:  Massimo Milione
Journal:  Endocrine       Date:  2017-04-17       Impact factor: 3.633

2.  Role of miR-101 in pheochromocytoma patients with SDHD mutation.

Authors:  Ligeng Zong; Lizhen Meng; Ruhui Shi
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Identification of miRNAs as potential new biomarkers for nervous system cancer.

Authors:  Yong Wang; Jinchuan Liang; Cuili Di; Guiliang Zhao; Yaqun Zhao
Journal:  Tumour Biol       Date:  2014-08-20

Review 4.  Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Authors:  Victoria L Martucci; Karel Pacak
Journal:  Curr Probl Cancer       Date:  2014-01-15       Impact factor: 3.187

Review 5.  The role of miRNAs in the pheochromocytomas.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen
Journal:  Tumour Biol       Date:  2015-10-13

6.  MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas.

Authors:  Samantha M Ruff; Reed I Ayabe; Parisa Malekzadeh; Meghan L Good; Michael M Wach; Melissa K Gonzales; Amit Tirosh; Naris Nilubol; Karel Pacak; Electron Kebebew; Dhaval Patel
Journal:  J Surg Res       Date:  2019-05-27       Impact factor: 2.192

Review 7.  What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?

Authors:  Thomas G Papathomas; Diederik P D Suurd; Alfred K Lam; Ronald R de Krijger; Karel Pacak; Arthur S Tischler; Menno R Vriens
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 8.  Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours.

Authors:  Alfred King-Yin Lam
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

Review 9.  Noncoding RNAs in endocrine malignancy.

Authors:  Jessica Kentwell; Justin S Gundara; Stan B Sidhu
Journal:  Oncologist       Date:  2014-04-09

Review 10.  MicroRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy.

Authors:  Peter Igaz; Ivan Igaz; Zoltán Nagy; Gábor Nyírő; Peter M Szabó; András Falus; Attila Patócs; Károly Rácz
Journal:  Cell Mol Life Sci       Date:  2014-10-09       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.